Afatinib: First Global Approval
作者： Rosselle T. Dungo , Gillian M. Keating
DOI: 10.1007/S40265-013-0111-6
关键词: Cancer research 、 Medicine 、 Epidermal growth factor receptor 、 Cancer 、 Afatinib 、 Lung cancer 、 Tyrosine kinase 、 European union 、 ErbB 、 Pharmacology 、 Autophosphorylation
摘要: … Afatinib, an irreversible inhibitor of the ErbB family of tyrosine kinases, is under development with Boehringer Ingelheim for the once-daily, oral treatment of cancer. Afatinib … of afatinib, …
springer.com
sci-hub.se 参考文章(54)
Bruce E. Brockstein, Management of Recurrent Head and Neck Cancer Drugs. ,vol. 71, pp. 1551- 1559 ,(2011) , 10.2165/11592540-000000000-00000
Giorgio Valabrega, Elena Geuna, Massimo Aglietta, Filippo Montemurro, Potential of afatinib in the treatment of patients with HER2-positive breast cancer Breast Cancer. ,vol. 4, pp. 131- 137 ,(2012) , 10.2147/BCTT.S25868
Gang Chen, Peter Kronenberger, Erik Teugels, Ijeoma Adaku Umelo, Jacques De Grève, Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab BMC Medicine. ,vol. 10, pp. 28- 28 ,(2012) , 10.1186/1741-7015-10-28
B Xu, SA Im, CS Huang, YH Im, J Ro, Q Zhang, R Arora, A Mehta, K Jung, DC Yeh, S Lee, J Jassem, M Wojtukiewicz, SC Chen, A Lahogue, M Uttenreuther-Fischer, SA Hurvitz, N Harbeck, M Piccart-Gebhart, LUX-Breast 1 Study Group, None, Abstract OT1-1-16: LUX-Breast 1: Randomized, Phase III trial of afatinib (BIBW 2992) and vinorelbine vs. trastuzumab and vinorelbine in patients with HER2-overexpressing metastatic breast cancer (MBC) failing one prior trastuzumab treatment* Cancer Research. ,vol. 72, ,(2012) , 10.1158/0008-5472.SABCS12-OT1-1-16
Bin-Chi Liao, Chia-Chi Lin, James Chih-Hsin Yang, First-Line Management of EGFR -Mutated Advanced Lung Adenocarcinoma: Recent Developments Drugs. ,vol. 73, pp. 357- 369 ,(2013) , 10.1007/S40265-013-0020-8
Michael S Gordon, David S Mendelson, Mitchell Gross, Martina Uttenreuther-Fischer, Mahmoud Ould-Kaci, Yihua Zhao, Peter Stopfer, David B Agus, None, A Phase I, open-label, dose-escalation study of continuous once-daily oral treatment with afatinib in patients with advanced solid tumors Investigational New Drugs. ,vol. 31, pp. 409- 416 ,(2013) , 10.1007/S10637-012-9904-9
John Marshall, Jimmy Hwang, Ferry A. L. M. Eskens, Herman Burger, Shakun Malik, Martina Uttenreuther-Fischer, Peter Stopfer, Mahmoud Ould-Kaci, Roger B. Cohen, Nancy L Lewis, A Phase I, open-label, dose escalation study of afatinib, in a 3-week-on/1-week-off schedule in patients with advanced solid tumors Investigational New Drugs. ,vol. 31, pp. 399- 408 ,(2013) , 10.1007/S10637-012-9890-Y
Vera Hirsh, Afatinib (BIBW 2992) development in non-small-cell lung cancer. Future Oncology. ,vol. 7, pp. 817- 825 ,(2011) , 10.2217/FON.11.62
Giulio Metro, Lucio Crinò, The LUX-Lung clinical trial program of afatinib for non-small-cell lung cancer. Expert Review of Anticancer Therapy. ,vol. 11, pp. 673- 682 ,(2011) , 10.1586/ERA.11.34
Martin Schuler, Ahmad Awada, Philipp Harter, Jean Luc Canon, Kurt Possinger, Marcus Schmidt, Jacques De Grève, Patrick Neven, Luc Dirix, Walter Jonat, Matthias W. Beckmann, Jochen Schütte, Peter A. Fasching, Nina Gottschalk, Tatiana Besse-Hammer, Frank Fleischer, Sven Wind, Martina Uttenreuther-Fischer, Martine Piccart, Nadia Harbeck, A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer Breast Cancer Research and Treatment. ,vol. 134, pp. 1149- 1159 ,(2012) , 10.1007/S10549-012-2126-1